Evidence map›Paper›PMID 41719510›Full record

ArticleJCO precision oncology2026

Foundation Model Based on Routine Magnetic Resonance Imaging for Brain Tumor Molecular Profiling and Progression Prediction.

Junxian Li, Renhe Liu, Yuchen Xing, Ximin Gao, Qiang Yin, Qian Su

Abstract read
In one paragraph

Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Junxian LiDepartment of Blood Transfusion, Key Laboratory of Cancer Prevention and Therapy, Tianjin, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China.
Renhe LiuDepartment of Diagnostic and Therapeutic Ultrasonography, Key Laboratory of Cancer Prevention and Therapy, Tianjin, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China.
Yuchen XingDepartment of Cancer Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China.
Ximin GaoDepartment of Cancer Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Tianjin, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China.
Qiang YinDepartment of Neurosurgery and Neuro-oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China.
Qian SuDepartment of Molecular Imaging and Nuclear Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University, Tianjin, China.ORCID 0000-0001-5828-1683

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo build a self-supervised magnetic resonance imaging (MRI) foundation model from routine clinical scans and to test whether it can support key glioma-related applications, including post-therapy imaging outcome characterization and molecular marker inference. MATERIALS AND

methodsWe created the Unified Multimodal Brain Imaging Foundation (UMBIF) model and pretrained it in a self-supervised manner using 51,029 routine brain MRI examinations collected across multiple institutions. Pretraining used a hybrid objective that couples masked-image reconstruction with contrastive representation learning to encourage anatomically and clinically informative embeddings. The pretrained UMBIF encoder was then adapted to downstream multicenter data sets to predict (1) post-treatment radiographic outcomes and (2) molecular biomarkers, including

resultsRelative to self-supervised initialization derived from natural-image corpora or from approaches emphasizing only large tumor-area crops (self-supervised learning [SSL]-ImageNet and SSL-Cerebral), the UMBIF encoder-decoder design captured richer, more task-relevant features and consistently improved downstream discrimination. The best pretrained model achieved an accuracy of 0.899 (AUC, 0.815) for post-treatment radiographic outcome characterization. For molecular profiling, it reached accuracies/AUCs of 0.898/0.916 for 1p/19q codeletion, 0.829/0.896 for

conclusionUMBIF showed robust transferability to both post-therapy imaging assessment and molecular status prediction in glioma. By leveraging large-scale self-supervised pretraining to boost performance while reducing dependence on manual annotations, the framework may facilitate more efficient and reliable diagnostic workflows.

Indexed as

Brain NeoplasmsGliomaMagnetic Resonance ImagingDisease ProgressionHumans

Identifiers

PMID41719510
PMCPMC12931859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.